NewGenIvf Group Limited Class A Ordinary Shares (NIVF)

FairStock Score: 59/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable competitive advantages, honest accounting, and a margin of safety. NewGenIvf operates fertility clinics in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Fertility services can be valuable, but they are local, capital-intensive, and competitive; I see no evidence of a durable moat in the supplied figures. The latest filed quarter, fiscal Q4 2025, showed revenue of $1.4M and a net loss of $7.7M—a negative 538.34% margin. That is a business burning far more than it earns. FairStock's calculations show ROCE of -36.94%, Piotroski F-Score of 3/9, and Altman Z-Score of 0.20, all pointing to financial distress. The reported ROE of 79.40% and debt-to-equity of 0.19 do not offset that; the ROE looks distorted, and the balance sheet is tiny. At the close on 2026-10-13, the price was $0.19 and market cap was $1.1M. FairStock's Graham Number is $1,565.92 with a 99.99% margin of safety, but I treat that as an artifact: a $7.7M quarterly loss cannot support a genuine Graham bargain. EV/EBITDA of 0.54 may look cheap, yet negative profits make it unreliable. The 52-week range of $0.06 to $171.00 shows violent speculation, not steady compounding. The revenue base is too small relative to the loss, and I cannot rely on growth figures without a named period in the supplied data. FairStock's Lynch category is none because only zero years of filed results are available, needing three. This is not the kind of predictable, financially sound enterprise I seek. I would need to see shrinking losses, stable revenue, and audited history before taking the numbers seriously.

In plain English: NewGenIvf provides fertility treatments such as in-vitro fertilization in Thailand, Cambodia, Hong Kong and Kyrgyzstan. The business looks weak right now: in fiscal Q4 2025 it lost $7.7 million on just $1.4 million of revenue, and it has very little history as a public company. At 19 cents a share, the price may look low, but the numbers are too unstable and loss-making to call it clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer